摘要
心臟衰竭是一種盛行率高且致死率相當高的疾病。自從心臟衰竭的治療指南發行後，陸續增補了新診斷與治療方法。2016年，歐洲|心臟學會和美國心臟病學會基金會/美國心臟學會/美國心臟衰竭學會公佈治療指南的更新，增列新藥物治療心臟衰竭。目前心臟衰竭患者，可從治療指南建議的藥物，包括血管張力素轉化酶抑制劑、血管張力素受體拮抗劑、乙型阻斷劑、礦物皮質激素/醛固酮受體拮抗劑、血管張力素受體-腦啡肽酶抑制劑(angiotensin receptor-neprilysin inhibitor)、竇房調節劑、與其他藥物，獲得良好的治療，不僅改善症狀，同時降低再住院率，與降低死亡率。
並列摘要
Heart failure (HF) is a common cause of morbidity and mortality. Since the publication of guidelines for the management of HF, new diagnostic and therapeutic options for HF have emerged. In 2016, both the European Society of Cardiology (ESC) and the American College of Cardiology Foundation /American Heart Association/ Heart Failure Society of America (ACCF/AHA/HFSA) have published updated versions of recommendations for the use of new pharmacological therapies for the treatment of HF. Medications used to treat HF include angiotensin converting enzyme inhibitors (ACEI), angiotensin receptor blocker (ARBs), beta-blockers, Mineralocorticoid/Aldosterone Receptor Antagonists (MRA), angiotensin receptor-neprilysin inhibitor (ARNI), sinoatrial modulator and other medications. Thus, HF patients may also benefit from a number of pharmacological interventions. They not only improve symptoms of HF, but also reduce rehospitalization and mortality rate.
被引用紀錄
延伸閱讀
- 殷偉賢（2013）。冠狀動脈心臟病治療新進展。臺灣醫界，56(2)，11-14。https://www.airitilibrary.com/Article/Detail?DocID=17263603-201302-201302200018-201302200018-11-14
- 殷偉賢（2013）。冠狀動脈心臟病治療新進展。中華民國內膜異位症婦女協會會刊，20(11&12)，5-8。https://doi.org/10.6498/EA.2013.20(11/12).1
- 李振德、黃少嵩（2021）。慢性心臟衰竭藥物治療理論與實證。臨床醫學月刊，88(5)，712-716。https://doi.org/10.6666/ClinMed.202111_88(5).0119
- Liu, W. P., & Chen, W. K. (2004). Non-Penetrating Cardiac Rupture. Mid-Taiwan Journal of Medicine, 9(1), 55-59. https://doi.org/10.6558/MTJM.2004.9(1).8
- 李烈（2011）。New Experience in Heart。志為護理-慈濟護理雜誌，10(3)，48-49。https://doi.org/10.6974/TCNJ.201106.0048